GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Invacare Corp (OTCPK:IVCRQ) » Definitions » Peter Lynch Fair Value

Invacare (Invacare) Peter Lynch Fair Value : N/A (As of Apr. 28, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Invacare Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.


The historical rank and industry rank for Invacare's Peter Lynch Fair Value or its related term are showing as below:



IVCRQ's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.6
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Invacare Peter Lynch Fair Value Historical Data

The historical data trend for Invacare's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invacare Peter Lynch Fair Value Chart

Invacare Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Peter Lynch Fair Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Invacare Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Invacare's Peter Lynch Fair Value

For the Medical Instruments & Supplies subindustry, Invacare's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Invacare's Price-to-Peter-Lynch-Fair-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Invacare's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Invacare's Price-to-Peter-Lynch-Fair-Value falls into.



Invacare Peter Lynch Fair Value Calculation

Invacare's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* N/A *-2.08
=N/A

Invacare's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.08.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Invacare  (OTCPK:IVCRQ) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 0 instead of 15 in this case.

Invacare's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=0.0135/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Invacare Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Invacare's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Invacare (Invacare) Business Description

Traded in Other Exchanges
N/A
Address
One Invacare Way, Elyria, OH, USA, 44035-4190
Invacare Corp makes and distributes medical equipment used in non-acute care settings. Its products are primarily sold to home medical equipment providers, residential living operators, distributors, and government health services. The firm sells products in three categories: mobility and seating, lifestyle, and respiratory therapy. Its mobility and seating products include power wheelchairs, custom manual wheelchairs, and positioning cushions. Its lifestyle products include manual wheelchairs, crutches, walkers, and homecare beds. Its respiratory products include stationary and portable oxygen concentrators and non-delivery oxygen technology. Invacare receives the largest proportion of revenue from sales in Europe.
Executives
Tenor Opportunity Master Fund, Ltd. 10 percent owner 810 SEVENTH AVENUE, SUITE 1905, NEW YORK NY 10019
Randel G Owen director C/O EMERGENCY MEDICAL SERVICES CORP, 6200 SOUTH SYRACUSE WAY, GREENWOOD VILLAGE CO 80111
Kimberly Herman director 3 HUNTINGTON QUADRANGLE, STE 25, MELVILLE NY 11747
Marec Elden Edgar director 1420 KENSINGTON ROAD, SUITE 220, OAK BROOK IL 60523
Elliot Bossen 10 percent owner 3100 TOWER BLVD, UNIVERSITY TOWER STE 1104, DURHAM NC 27707
Silverback Asset Management Llc 10 percent owner 1414 RALEIGH ROAD, SUITE 250, CHAPEL HILL NC 27517
Peter J. Kuipers director 590 E. MIDDLEFEILD ROAD, MOUNTAIN VIEW CA 94043
Tenor Capital Management Co., L.p. 10 percent owner 810 SEVENTH AVENUE, SUITE 1905, NEW YORK NY 10019
Pm Manager Fund, Spc-segregated Portfolio 33 10 percent owner 190 ELGIN AVE, GEORGE TOWN, GRAND CAYMAN E9 KYI-9005
Dov Gertzulin 10 percent owner C/O DG CAPITAL MANAGEMENT, LLC, 460 PARK AVENUE, 22ND FLOOR, NEW YORK NY 10022
Dg Capital Management, Llc 10 percent owner 460 PARK AVENUE, 22ND FLOOR, NEW YORK NY 10022
Endurant Capital Management Lp 10 percent owner 66 BOVET ROAD, SUITE 353, SAN MATEO CA 94402
Abraham T Han director 51 MIDLAND AVENUE, WYCKOFF NJ 07481
Dg Value Partners Ii Master Fund, Lp 10 percent owner 460 PARK AVENUE, 22ND FLOOR, NEW YORK NY 10022
Quang Minh Pham 10 percent owner 66 BOVET ROAD, SUITE 353, SAN MATEO CA 94402

Invacare (Invacare) Headlines

From GuruFocus

Invacare Announced Sponsorship Agreement With Coach Rob Mendez

By Business Wire Business Wire 10-06-2021

Invacare Corporation Announces Additional Draw of Term Loans

By Business Wire Business Wire 12-27-2022